PVH Corp. has a clear opportunity to boost sales and margins, supported by strong brand awareness and social engagement, especially for Calvin Klein. The company focuses on growing e-commerce and key product categories like underwear, denim, and fragrance, with denim showing particular promise. While the turnaround has taken longer than expected, early signs include revenue growth and pricing power gains. Challenges remain in European wholesale, but improvements are expected in the latter half of next year.
PVH Corp.'s path to higher sales and margins is presented here alongside a snapshot of the Consumer Cyclical sector on Pluang as of Oct 07, 2026 01:21 WIB. Out of 112 priced US stocks in this sector, 73 advanced while 39 declined. Notably, Norwegian Cruise Line Holdings Ltd (NCLH) and Royal Caribbean Cruises Ltd (RCL) both saw gains over 4%, with NCLH at USD 15.50 and RCL at USD 286.52, each enjoying 100% buy order activity, contrasting with MakeMyTrip Ltd (MMYT) which fell 4.20% to USD 43.11 and had a shorter typical hold time of 12 days.
Callan JMB has received and will install a QuickStrip™ oral thin-film production line from Rapid Dose Therapeutics at its Texas facility, marking a key step in expanding its domestic pharmaceutical manufacturing. This new capability aims to produce f...
Known, a company developing accountability infrastructure for autonomous AI, announced that Edna Conway, former senior security executive at Microsoft and Cisco, has joined its Advisory Council. Conway brings extensive experience in cybersecurity and...
A SEON survey of 2,026 U.S. adults reveals that while 68% use AI agents weekly for personal tasks, half are uncomfortable letting AI handle credit card purchases. Only 15% would share financial info with AI, and 43% lack confidence in spotting fraudu...
Radiopharm Theranostics announced progress in its oncology radiopharmaceutical pipeline, including preparing for a pivotal Phase 3 imaging trial of RAD101 for recurrent brain metastases after a successful FDA End-of-Phase 2 meeting. The company also ...
UroGen Pharma has dosed the first patient in a Phase 1 trial testing UGN-501, a next-generation oncolytic virus for non-muscle invasive bladder cancer (NMIBC). The trial aims to evaluate the safety and tolerability of UGN-501 administered directly in...
